Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 15/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22726993 | 0.84 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL29504016 | 0.84 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL21591177 | 0.82 | TAS1R3 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16666098 | 0.80 | HCRTR1 (0.47) | HCRTR1HCRTR2CA12CA1CA2 | |
| SCHEMBL29954061 | 0.79 | CTSD (0.55) | — | |
| SCHEMBL16666094 | 0.79 | HCRTR1 (0.46) | HCRTR1HCRTR2CA12CA1CA2 | |
| SCHEMBL14880049 | 0.77 | CA1 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10414462 | 0.77 | CA1 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29954073 | 0.75 | FAAH (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL6329502 | 0.74 | CA1 (0.59) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737443-A1 | SALT-INDUCIBLE KINASE INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Tanabe Pharma Corporation (JP) | 2026-05-06 | — | — | EP | disclosed |
| US-12606554-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | ONCO3R THERAPEUTICS BV (BE) | 2026-04-21 | — | — | US | disclosed |
| US-20260062387-A1 | SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-03-05 | — | — | US | disclosed |
| US-12391679-B2 | Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases | ONCO3R THERAPEUTICS BV (BE) | 2025-08-19 | — | — | US | disclosed |
| WO-2025068090-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2025-04-03 | — | — | WO | disclosed |
| CN-113924146-B | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | 加拉帕戈斯股份有限公司 | 2024-12-10 | — | — | CN | disclosed |
| WO-2024242169-A1 | SALT-INDUCIBLE KINASE INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 田辺三菱製薬株式会社 | 2024-11-28 | — | — | WO | disclosed |
| EP-3976189-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2024-07-03 | — | — | EP | disclosed |
| US-20220340548-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-10-27 | — | — | US | disclosed |
| US-20220235048-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-07-28 | — | — | US | disclosed |
| EP-3976189-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | Galapagos N.V. (BE) | 2022-04-06 | — | — | EP | disclosed |
| EP-3976178-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | Galapagos N.V. (BE) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020239658-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020239660-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062387-A1 | SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | SIK1, SIK3, SIK2 | HCRTR1 4181/4885HCRTR2 3720/4885CA12 4039/4885 |
| US-20220340548-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | IL1B, IL1A, IL36G | HCRTR1 903/4885HCRTR2 2147/4885CA12 697/4885 |
| US-20220235048-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | IL1A, IFNG, COL1A1 | HCRTR1 444/4885HCRTR2 1597/4885CA12 528/4885 |
| US-12606554-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | IL23R, IL2, IL36G | HCRTR1 142/4885HCRTR2 242/4885CA12 591/4885 |
| US-12391679-B2 | Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases | IL5, IL15, IL1A | HCRTR1 1679/4885HCRTR2 2900/4885CA12 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.